Eledon Pharmaceuticals(ELDN) - 2025 Q4 - Annual Report

Financial Position - As of December 31, 2025, there were 75,430,033 shares of common stock outstanding and pre-funded warrants and common stock warrants to purchase 51,781,090 shares of common stock[164]. - The company currently lacks sufficient liquidity to fund the continued clinical development of tegoprubart for ALS without additional financing[170]. - The company maintains cash deposits exceeding FDIC insurance limits, with approximately 78% of total cash previously held at Silicon Valley Bank before its failure[174]. - The company has diversified its cash deposits into money market funds, U.S. treasuries, and U.S. government agency securities, with less than 5% of total cash in FDIC insured accounts as of the report date[174]. Drug Development Risks - The company has invested substantially all efforts and financial resources in the development of its lead drug candidate, tegoprubart, with no products currently having gained regulatory approval[165]. - The company does not expect to generate product revenues for several years, if ever, heavily depending on the successful development and commercialization of drug candidates[165]. - The company faces significant risks and uncertainties in drug development, including potential delays and increased costs due to regulatory requirements and clinical trial challenges[175]. - The company may experience delays in clinical trials due to various factors, including regulatory approvals and recruitment challenges[177]. - The company may incur additional costs or experience delays in completing the formulation and commercialization of its product candidates[175]. - Delays in patient enrollment for clinical trials may lead to increased development costs, potentially causing a decline in the company's value and limiting financing options[180]. - The ongoing conflict in Ukraine and the Middle East may disrupt clinical trial activities in affected regions, impacting the company's plans[184]. Regulatory Challenges - The company has not received marketing approval for any product candidates, which could materially impair revenue generation capabilities[190]. - Regulatory approval processes are expensive and can take several years, with significant risks of delays or refusals based on various factors[190]. - The company is subject to various regulatory changes that could complicate marketing approval and commercialization of its product candidates[197]. - Regulatory authorities may impose extensive post-marketing requirements, which could lead to additional costs and operational challenges[194]. - Regulatory authorities may impose additional restrictions or withdraw approval of products if safety concerns arise post-approval[219]. Market and Competition - The development and commercialization of new drug products is highly competitive, with significant competition from major pharmaceutical and biotechnology companies[221]. - Tegoprubart is expected to face competition from numerous FDA-approved therapeutics for transplant rejection, including PROGRAF, ASTAGRAF XL, and others[223]. - The company anticipates pricing pressures due to the availability of generic products, which may lead to reduced commercial opportunities[226]. - Market acceptance of product candidates is uncertain and depends on various factors, including efficacy, safety, and pricing[215]. - There is significant uncertainty regarding insurance coverage and reimbursement for newly approved products, which could limit marketability and revenue generation[228]. Operational Challenges - The company currently lacks a marketing and sales force, which could hinder the effective commercialization of product candidates if approved[220]. - The company faces challenges in recruiting and retaining qualified personnel, which is critical for achieving development and commercialization objectives[189]. - The company depends on CROs and other third parties for clinical testing and research activities, which may affect the pace of development and commercialization[242]. - Reliance on third-party manufacturers for drug production poses risks related to quality, cost, and supply chain disruptions[234]. - The company may face challenges in establishing agreements with third-party manufacturers on acceptable terms, which could affect production timelines[239]. Intellectual Property and Legal Risks - The patent prosecution process is costly and time-consuming, potentially hindering the ability to secure necessary intellectual property protections[246]. - The company may face significant costs and time associated with lawsuits to protect or enforce its patents or other intellectual property, which could adversely affect its business[253]. - The company’s competitors may infringe its patents, requiring the company to file infringement claims that can be expensive and time-consuming[255]. - The company’s ability to protect its intellectual property rights is uncertain, and changes in patent laws could diminish the value of its patents[249]. - The company may need to license certain intellectual property from third parties, and failure to obtain such licenses on commercially reasonable terms could materially harm its business[256]. - The company may be subject to claims of misappropriation of trade secrets from former employers of its personnel, which could result in substantial costs and loss of valuable intellectual property rights[258]. Compliance and Cybersecurity - The company is subject to various healthcare laws, which could lead to significant civil, criminal, and administrative penalties if found in violation[204]. - Compliance with healthcare laws may involve substantial costs, and non-compliance could result in reputational harm and diminished profits[206]. - The company relies on information systems that are vulnerable to cybersecurity incidents, which could materially disrupt operations and harm financial condition[209]. - Loss of clinical trial data could significantly increase costs and delay regulatory approval efforts[210]. - The company may face substantial fines and penalties for non-compliance with data protection laws, particularly in the European Economic Area under GDPR[213]. Financial Strategy - The company expects its stock price to be volatile, influenced by various factors including uncertainties regarding financial condition and regulatory approvals for product candidates[259]. - The company does not expect to pay any cash dividends in the foreseeable future, focusing instead on retaining earnings to fund business development and growth[266]. - The company has previously identified and remediated a material weakness in its internal control over financial reporting, which could impact the accuracy and timeliness of financial reporting[264]. - Increased governmental and third-party payer efforts to cap healthcare costs may limit coverage and reimbursement for new products, impacting revenue potential[230].